We serve Chemical Name:N-(aminoiminomethyl)-4-Pyridinecarboxamide CAS:6531-74-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-(aminoiminomethyl)-4-Pyridinecarboxamide
CAS.NO:6531-74-4
Synonyms:N-(aminoiminomethyl)-4-Pyridinecarboxamide
Molecular Formula:C7H8N4O
Molecular Weight:164.16462
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-(aminoiminomethyl)-4-Pyridinecarboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(aminoiminomethyl)-4-Pyridinecarboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(aminoiminomethyl)-4-Pyridinecarboxamide Use and application,N-(aminoiminomethyl)-4-Pyridinecarboxamide technical grade,usp/ep/jp grade.
Related News: But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. N-(aminoiminomethyl)-4-Pyridinecarboxamide manufacturer ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib. N-(aminoiminomethyl)-4-Pyridinecarboxamide supplier But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. N-(aminoiminomethyl)-4-Pyridinecarboxamide vendor Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. N-(aminoiminomethyl)-4-Pyridinecarboxamide factory ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib.